05.01.21

Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercept

Source: Novartis

12.15.20

Novartis Reports Positive Topline Results From Second Phase 3 Trial of Beovu in Patients With DME

Source: Novartis

10.05.20

New Phase 3 Analysis Demonstrates Beovu Showed Improvement in BCVA in Wet AMD Patients With Early Persistent Fluid

Source: Novartis

10.05.20

Beovu Now Available in Canada, Receives Positive Reimbursement Recommendation

Source: Novartis

09.15.20

European Medicines Agency (EMA) Approves Safety Label Update for Novartis’ Beovu

Source: Novartis

09.14.20

Novartis Reports Topline Results From the First Phase 3 Trial of Beovu Versus Aflibercept in DME Patients

Source: Novartis

07.27.20

New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercept

Source: Novartis

06.08.20

Novartis Provides Update On Use and Safety of Beovu (brolucizumab)

Source: Eyewire News

03.02.20

Novartis Provides Update on Use and Safety of Beovu in Patients With Wet AMD

Source: Novartis

02.25.20

Novartis Responds to ASRS Note Raising Safety Concerns With Wet AMD Drug Beovu

Source: Eyewire News

View more stories